Immunotherapy Combinations Show Dramatic Survival Gains in Mesothelioma Patients
Key Insights
Long-term follow-up data from the CheckMate 743 trial revealed that 14% of mesothelioma (search) patients receiving nivolumab plus ipilimumab were alive at 5 years, compared to 6% on chemotherapy alone.
For patients with non-epithelioid mesothelioma (search), 5-year survival improved dramatically from approximately 1% to 12%, representing a landmark therapeutic breakthrough.
The KEYNOTE-483 trial demonstrated that pembrolizumab combined with chemotherapy achieved tumor shrinkage or control in 62% of patients, following FDA approval in 2024.
Breakthrough immunotherapy combinations are delivering unprecedented survival benefits for patients with mesothelioma (search), a rare and aggressive asbestos-caused cancer (search) that affects approximately 3,000 Americans annually. New long-term data from pivotal clinical trials demonstrate that dual immunotherapy regimens are more than doubling five-year survival rates compared to traditional chemotherapy approaches.
CheckMate 743 Trial Delivers Landmark Survival Data
Long-term follow-up data from the CheckMate 743 study showed that 14% of patients receiving nivolumab plus ipilimumab (Opdivo® + Yervoy®) were alive at 5 years, compared to 6% on chemotherapy alone. The survival benefit was particularly striking for patients with non-epithelioid mesothelioma (search), where 5-year survival improved from approximately 1% to 12%.
"Things have improved somewhat, but not as much as I would like. That's why we continue to do research - to try and make the treatment better. The rate of research is accelerating substantially," said Dr. Edward Levine, a mesothelioma (search) specialist at Atrium Health Wake Forest Baptist (search).
FDA-Approved Combination Therapy Shows Strong Response Rates
The KEYNOTE-483 trial demonstrated that pembrolizumab (Keytruda®) combined with chemotherapy shrank or controlled tumors in 62% of patients. This combination therapy received FDA approval in 2024, providing another treatment option for patients facing this challenging diagnosis.
Expanding Treatment Pipeline
The therapeutic landscape for mesothelioma (search) continues to evolve rapidly, with more than 50 clinical trials actively recruiting patients as of May 2026. Emerging treatments showing promise in early-stage trials include CAR T-cell therapy, gene therapy, photodynamic therapy, and proton beam therapy.
Advances in Early Detection
Diagnostic improvements are also contributing to better patient outcomes. Advanced techniques including cryobiopsy, liquid biopsy, and AI-assisted imaging analysis are helping doctors detect mesothelioma (search) earlier and match patients to more targeted treatments. These advances are particularly crucial given that mesothelioma is often not detected until its later stages.
The progress in mesothelioma (search) treatment represents a significant shift for a cancer (search) that has historically carried a poor prognosis. With the accelerating pace of research and the growing number of available clinical trials, patients and families now have access to more treatment options and improved survival prospects than ever before.